189 related articles for article (PubMed ID: 20617279)
41. Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG.
Leide-Svegborn S
Radiat Prot Dosimetry; 2010; 139(1-3):208-13. PubMed ID: 20167792
[TBL] [Abstract][Full Text] [Related]
42. 18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours.
Nanni C; Rubello D; Castellucci P; Farsad M; Franchi R; Rampin L; Gross MD; Al-Nahhas A; Fanti S
Biomed Pharmacother; 2006 Nov; 60(9):593-606. PubMed ID: 16978824
[TBL] [Abstract][Full Text] [Related]
43. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
Menda Y; Graham MM
Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
[TBL] [Abstract][Full Text] [Related]
44. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis.
King AD; Ma BB; Yau YY; Zee B; Leung SF; Wong JK; Kam MK; Ahuja AT; Chan AT
Br J Radiol; 2008 Apr; 81(964):291-8. PubMed ID: 18344274
[TBL] [Abstract][Full Text] [Related]
45. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
46. Clinical applications of positron emission tomography-computed tomography in oncology.
Kumar R; Halanaik D; Malhotra A
Indian J Cancer; 2010; 47(2):100-19. PubMed ID: 20448371
[TBL] [Abstract][Full Text] [Related]
47. Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer.
Gondi V; Bradley K; Mehta M; Howard A; Khuntia D; Ritter M; Tomé W
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):187-95. PubMed ID: 17189070
[TBL] [Abstract][Full Text] [Related]
48. Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern.
Chowdhury FU; Sheerin F; Bradley KM; Gleeson FV
Clin Radiol; 2009 Jul; 64(7):675-81. PubMed ID: 19520211
[TBL] [Abstract][Full Text] [Related]
49. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.
Antoch G; Saoudi N; Kuehl H; Dahmen G; Mueller SP; Beyer T; Bockisch A; Debatin JF; Freudenberg LS
J Clin Oncol; 2004 Nov; 22(21):4357-68. PubMed ID: 15514377
[TBL] [Abstract][Full Text] [Related]
50. [PET-CT scan: a major progress toward fused, metabolic and functional images].
Rusu V; Răileanu I
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):650-6. PubMed ID: 17571561
[TBL] [Abstract][Full Text] [Related]
51. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
52. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
53. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Cancer Radiother; 2005 Sep; 9(5):304-15. PubMed ID: 16087377
[TBL] [Abstract][Full Text] [Related]
54. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
[TBL] [Abstract][Full Text] [Related]
55. EANM procedure guidelines for brain PET imaging using [
Guedj E; Varrone A; Boellaard R; Albert NL; Barthel H; van Berckel B; Brendel M; Cecchin D; Ekmekcioglu O; Garibotto V; Lammertsma AA; Law I; Peñuelas I; Semah F; Traub-Weidinger T; van de Giessen E; Van Weehaeghe D; Morbelli S
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):632-651. PubMed ID: 34882261
[TBL] [Abstract][Full Text] [Related]
56. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
[TBL] [Abstract][Full Text] [Related]
57. Evolving role of 18F-FDG-PET/CT for the body tumor and metastases in pediatrics.
Chen Z; Li X; Li F; Ouyang Q; Yu T
Eur J Radiol; 2010 Sep; 75(3):329-35. PubMed ID: 20576385
[TBL] [Abstract][Full Text] [Related]
58. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
59. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
60. [Clinical usefulness of FDG-PET in oncology].
Sasaki M
Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
